Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs
Bakhos A. Tannous(Massachusetts General Hospital), Thomas Würdinger(Amsterdam University Medical Centers), Nathanael S. Gray(Stanford University), Olaf van Tellingen(Dutch Cancer Society), Dirk Geerts(Amsterdam UMC Location University of Amsterdam), Tonny Lagerweij(Amsterdam University Medical Centers), Mariam Kerami(Harvard University), Grant K. Lewandrowski(Harvard University), David P. Noske(Amsterdam University Medical Centers), Laurine E. Wedekind(Amsterdam University Medical Centers), Almuth F. Keßler(Harvard University), W. Peter Vandertop(Amsterdam UMC Location Vrije Universiteit Amsterdam), R. Jonas A. Nilsson(Umeå University), Lotte Hiddingh, Nik Sol(Harvard University), Nicholas Kwiatkowski(Woomera Therapeutics), Marco Barazas(Massachusetts General Hospital), Johanna M. Niers(Harvard University), Philip C. De Witt Hamer(Amsterdam UMC Location VUmc), Jinhua Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenjun Zhou(Central South University), Petra M. van der Stoop(Harvard University), Carsten Hagemann(Universitätsklinikum Würzburg)
Cited by 131
Related Papers
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
|The Journal of Experimental Medicine|2007|2.3k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k